IL300285A - Formulations of triphenyl calcilytic compounds - Google Patents
Formulations of triphenyl calcilytic compoundsInfo
- Publication number
- IL300285A IL300285A IL300285A IL30028523A IL300285A IL 300285 A IL300285 A IL 300285A IL 300285 A IL300285 A IL 300285A IL 30028523 A IL30028523 A IL 30028523A IL 300285 A IL300285 A IL 300285A
- Authority
- IL
- Israel
- Prior art keywords
- tablet formulation
- weight
- amount
- present
- tablet
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061050P | 2020-08-04 | 2020-08-04 | |
| PCT/US2021/044295 WO2022031666A1 (en) | 2020-08-04 | 2021-08-03 | Formulations of triphenyl calcilytic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL300285A true IL300285A (en) | 2023-04-01 |
Family
ID=77431430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL300285A IL300285A (en) | 2020-08-04 | 2021-08-03 | Formulations of triphenyl calcilytic compounds |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20220040112A1 (enExample) |
| EP (1) | EP4192438A1 (enExample) |
| JP (2) | JP7827696B2 (enExample) |
| KR (1) | KR20230106582A (enExample) |
| CN (1) | CN116648243A (enExample) |
| AR (1) | AR123147A1 (enExample) |
| AU (1) | AU2021320147B2 (enExample) |
| BR (1) | BR112023002107A2 (enExample) |
| CA (1) | CA3188044A1 (enExample) |
| IL (1) | IL300285A (enExample) |
| MX (1) | MX2023001438A (enExample) |
| TW (1) | TWI924683B (enExample) |
| WO (1) | WO2022031666A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116648243A (zh) | 2020-08-04 | 2023-08-25 | 柯西立提克斯疗法有限公司 | 三苯基钙敏感化合物的制剂 |
| MX2023003129A (es) * | 2020-09-18 | 2023-08-04 | Calcilytix Therapeutics Inc | Compuestos trifenil-calciliticos para el tratamiento de hipocalcemia autosomica dominante tipo 1 (adh1). |
| WO2024160842A1 (en) | 2023-01-30 | 2024-08-08 | Medizinische Universität Wien | Use of calcilytics for preventing or treating hypoparathyroidism associated with anterior neck surgery |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20050460A1 (es) | 2003-04-23 | 2005-07-08 | Japan Tobacco Inc | COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO) |
| EP1964548A1 (en) * | 2007-03-02 | 2008-09-03 | Novartis AG | Pharmaceutical compositions comprising a calcilytic agent |
| SG174564A1 (en) * | 2009-03-26 | 2011-10-28 | Japan Tobacco Inc | Process for producing carboxylic acid compound |
| ES2900353T3 (es) * | 2010-04-07 | 2022-03-16 | Vertex Pharma | Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas |
| GB201217330D0 (en) * | 2012-09-28 | 2012-11-14 | Univ Cardiff | Therapeutic for treating inflammatory lung disorders |
| BR112020013073A2 (pt) | 2017-12-29 | 2020-12-01 | Biomarin Pharmaceutical Inc. | composto, composto, estereoisômero único ou mistura de estereoisômeros ou sal farmaceuticamente aceitável, composição farmacêutica, método de tratamento de uma doença ou distúrbio e composto ou sal farmaceuticamente aceitável do mesmo |
| WO2021029517A1 (en) | 2019-08-13 | 2021-02-18 | Dongguk University Industry-Academic Cooperation Foundation | Pharmaceutical composition for improving or treating post-surgical hypoparathyroidism and treatment method using the same |
| GB201918586D0 (en) * | 2019-12-17 | 2020-01-29 | Patterson James | Engineered platelets for targeted delivery of a therapeutic agent |
| CN116648243A (zh) | 2020-08-04 | 2023-08-25 | 柯西立提克斯疗法有限公司 | 三苯基钙敏感化合物的制剂 |
| MX2023003129A (es) | 2020-09-18 | 2023-08-04 | Calcilytix Therapeutics Inc | Compuestos trifenil-calciliticos para el tratamiento de hipocalcemia autosomica dominante tipo 1 (adh1). |
-
2021
- 2021-08-03 CN CN202180066180.1A patent/CN116648243A/zh active Pending
- 2021-08-03 CA CA3188044A patent/CA3188044A1/en active Pending
- 2021-08-03 MX MX2023001438A patent/MX2023001438A/es unknown
- 2021-08-03 BR BR112023002107A patent/BR112023002107A2/pt unknown
- 2021-08-03 JP JP2023507979A patent/JP7827696B2/ja active Active
- 2021-08-03 AU AU2021320147A patent/AU2021320147B2/en active Active
- 2021-08-03 WO PCT/US2021/044295 patent/WO2022031666A1/en not_active Ceased
- 2021-08-03 KR KR1020237007456A patent/KR20230106582A/ko active Pending
- 2021-08-03 IL IL300285A patent/IL300285A/en unknown
- 2021-08-03 EP EP21758555.3A patent/EP4192438A1/en active Pending
- 2021-08-03 US US17/392,720 patent/US20220040112A1/en not_active Abandoned
- 2021-08-04 AR ARP210102174A patent/AR123147A1/es unknown
- 2021-08-04 TW TW110128669A patent/TWI924683B/zh active
-
2023
- 2023-06-29 US US18/216,536 patent/US12357576B2/en active Active
-
2026
- 2026-02-26 JP JP2026029931A patent/JP2026086851A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023002107A2 (pt) | 2023-03-07 |
| CN116648243A (zh) | 2023-08-25 |
| AR123147A1 (es) | 2022-11-02 |
| US12357576B2 (en) | 2025-07-15 |
| EP4192438A1 (en) | 2023-06-14 |
| MX2023001438A (es) | 2023-06-15 |
| JP7827696B2 (ja) | 2026-03-10 |
| TW202220642A (zh) | 2022-06-01 |
| AU2021320147B2 (en) | 2026-07-30 |
| US20220040112A1 (en) | 2022-02-10 |
| CA3188044A1 (en) | 2022-02-10 |
| JP2026086851A (ja) | 2026-05-26 |
| KR20230106582A (ko) | 2023-07-13 |
| JP2023536667A (ja) | 2023-08-28 |
| WO2022031666A1 (en) | 2022-02-10 |
| US20240074978A1 (en) | 2024-03-07 |
| AU2021320147A1 (en) | 2023-03-30 |
| TWI924683B (zh) | 2026-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265777B2 (en) | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
| IL279039B1 (en) | Pharmaceutical combination, composition and combination formulation comprising glucokinase activator and dpp-iv inhibitor, and preparation method and use thereof | |
| US12357576B2 (en) | Formulations of triphenyl calcilytic compounds | |
| IL290727B1 (en) | A formulation for inhibiting the formation of 5-ht 2b agonists and methods of using the same | |
| IL295341A (en) | Compositions and methods for the treatment of diseases improved by the activation of muscarinic receptors | |
| IL275115B2 (en) | Bis-choline tetrathiolmolybdate for the treatment of Wilson's disease | |
| IL259493A (en) | Solid dispersions containing sgc actuator | |
| IL295490A (en) | omecamtiv mecarbil tablet | |
| NZ574200A (en) | Methods and medicaments for administration of ibuprofen and famotidine | |
| IL280937B1 (en) | Vitamin d pediatric dosage forms, methods of making and using | |
| IL290955B (en) | Compounds for the treatment of glycogen storage disorders | |
| IL298872A (en) | Dosage forms of eclobrutinib maleate | |
| IL305576A (en) | Objetive for the treatment of dementia | |
| IL302718A (en) | A tablet for use in the treatment of Huntington's disease and a method for its preparation | |
| IL301409A (en) | Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1) | |
| IL273988B2 (en) | Cannabidiol and chitosan compositions and methods of using the same | |
| IL303961A (en) | Therapeutic methods using VADADUSTAT | |
| IL297218A (en) | Pharmaceutical formulations | |
| IL296196A (en) | Methods of administering elagolix | |
| US20240100088A1 (en) | Novel formulation for treating copper metabolism-associated diseases or disorders | |
| IL305191A (en) | Methods for treating hereditary chylomicronemia syndrome | |
| IL292982A (en) | Methods of Administering Voxlotor | |
| WO2026088136A1 (en) | Methods of treating a neurodegenerative disease | |
| Dharmalingam et al. | Comparative Quality Control Evaluation of Atenolol Tablets Marketed in Kuala Lumpur, Malaysia. | |
| IL309056A (en) | A preparation containing a DIHYDROPYRIDAZINE-3,5-DIONE derivative |